<DOC>
	<DOCNO>NCT00425035</DOCNO>
	<brief_summary>Multicenter , 2-part , multiple-dose study design evaluate safety effectiveness weekly administration panitumumab subject renal carcinoma . Part 1 initiated 2001 present . Part 2 design examine dose 2.5 mg/kg/wk 2 cohort .</brief_summary>
	<brief_title>Safety Efficacy Study ABX-EGF Patients With Renal Cancer , Part 2</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Able comprehend sign IRB approve Informed Cosent Form Male female 18 year age old Female patient post menopausal ( menstrual period minimum six month ) , surgically sterilize , use oral implanted contraceptive , double barrier birth control , IUD negative serum pregnancy test upon entry study ; male patient willing use contraception upon enrollment study Pathologic diagnosis renal cell carcinoma fine needle aspirate tissue biopsy Prior nephrectomy Prior Therapy : 1 . Cohort 1 : Previously receive fail one prior biotherapy , define IL2 therapy interferonalpha ( alone combination ) ; Karnosky score &gt; = 70 % 2 . Cohort 2 : No prior therapy except nephrectomy fall within Motzer intermediate group one two risk factor , define teh Study Design section . Has bidimensionally measurable disease Has tumor tissue available diagnostics ( acceptable : biopsy , nephrectomy tissue , fine needle aspirate , archive tissue formalin fix paraffin embed ) . In case fresh biopsy obtain , biopsy divide two ; one half formalin fix , half frozen . Tumor sample must receive central laboratory prior patient regisration . Adequate hematologic data , follow : 1 . ANC &gt; 1.5 x 109/L 2 . Platelet count &gt; 100x 109/L Adequate renal function , follow : 1 . Creatinine &lt; = 2.2mg/dL Adequate hepatic function , follow : 1 . Alkaline phosphatase &lt; = 3x ULN 2 . AST &lt; = 3x ULN 3 . ALT &lt; = 3x ULN 4 . Total bilirubin &lt; = 1.5x ULN Brain metastases Cohort 1 : Hypercalcemia ( calcium level outside upper limit normal ; antihypercalcemic treatment allow ) Cancer therapy within 30 day ABXEGF infusion ( hormone therapy allow ; steroid therapy allow replacement therapy ) Use investigational drug within 30 day ABXEGF infusion Prior treatment antiEGFr agent Left ventricular ejection fraction &lt; 45 % , measure MUGA Scan Myocardial infarction within one year prior enter study Has cancer active require treatment within past 5 year ( prior renal cell carcinoma , basal cell carcinoma , cervical carcinoma situ allow ) Pregnant breast feed female ; male female childbearing potential ( define : post menarche biologically capable become pregnant ) unwilling use birth control ( define inclusion criterion ) 1 month follow treatment Known HIV positive History chronic medical psychiatric condition laboratory abnormality opinion Investigator may increase risk associate study participation study drug administration may interfere interpretation study result Allergy ingredient study medication Staphylococcus Protein A</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Renal Cancer</keyword>
</DOC>